Last updated on April 24, 2014 at 12:48 EDT

immatics Closes EUR34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer

October 15, 2013

TUEBINGEN, Germany, October 15, 2013 /PRNewswire/ –

        - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in
          2014 and final data in 2015
        - Funding secured within existing investor group

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing
advanced multi-peptide cancer vaccines that are active against cancer, today announced
that it has closed a EUR34 million Series D financing round.

The funding round was supported by existing investors including dievini Hopp Biotech
holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the
fundraising, immatics will receive the first EUR12 million tranche of funding immediately.

The new funds will enable immatics to conclude the development of its lead vaccine
IMA901, including completing all of the activities necessary to prepare for regulatory
filings in the US and Europe. IMA901 – a cancer vaccine comprising 10 different
tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the
majority of patients suffering from renal cell carcinoma (RCC) – is in a pivotal phase 3
trial. It has orphan drug designation in the US and Europe for the treatment of RCC in
HLA-A*02 positive patients.

The phase 3 trial is designed to evaluate overall survival with IMA901 in combination
with sunitinib (Sutent(R), Pfizer), the current standard first-line therapy, compared with
sunitinib alone in patients with metastatic and/or locally advanced RCC. The trial has
completed inclusion of 339 patients at sites in the US and Europe. Interim overall
survival results are expected in 2014, with final data in 2015.

The phase 3 trial builds on the positive phase 2 study with IMA901 in advanced RCC
patients. The trial showed that patients who produced an immune response to two or more of
the TUMAPs contained in IMA901 had a significantly longer survival, as published in Nature
Medicine in 2012.[1]

Paul Higham, CEO of immatics, said: “We are pleased that our existing investors have
demonstrated their continued confidence in immatics and the novel cancer vaccines that we
are able to generate using our unique, rational TUMAP-based approach to cancer
immunotherapy. This financing will allow us to complete the full phase 3 development of
IMA901 and prepare regulatory submission packages for the US and Europe. There is a clear
need for novel cancer therapies that can deliver prolonged survival while maintaining a
good quality of life. We remain hopeful that IMA901 will deliver a significant improvement
for patients with renal cell cancer.”

Peter Chambre, Chairman of immatics’ Board, said: “The IMA901 results to date have
demonstrated that immatics’ vaccines have the potential to significantly extend the life
of renal cancer patients. I am delighted that our current investors have committed to
backing what we believe is a very promising cancer vaccine portfolio and cancer
immunotherapy approach and look forward to the IMA901 phase 3 results in the near future.”


1. Walter S, Weinschenk T et al. 2012. Multipeptide immune response to cancer vaccine
IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature
Medicine, published online: 29 July 2012.

About IMA901

IMA901 is a rationally designed cancer vaccine comprising 10 different
tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the
majority of patients suffering from renal cell carcinoma (RCC). IMA901 is a peptide-based
vaccine with a stable, off-the-shelf formulation and robust and easily scalable

About immatics

immatics biotechnologies is a clinical-stage biopharmaceutical company developing
advanced therapeutic vaccines that are active against cancer. immatics’ lead product,
IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2
trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported
improved overall survival data in patients with advanced colorectal cancer (phase 1/2
study completed), and IMA950, which is in phase 1 in patients with glioma.

immatics’ unique and world-leading technology platform XPRESIDENT(R)discovers novel
relevant cancer antigens known to be expressed on tumor cells. These tumor-associated
peptides (TUMAPs) constitute the basis for developing therapeutic cancer vaccines and
other immunotherapies, including peptide-targeting compounds such as antibodies and
soluble T-cell receptors. In contrast to widely used existing in silico and indirect
methods to identify peptide antigens, immatics’ TUMAPs are confirmed to be naturally
expressed in primary cancer tissue.

immatics’ vaccines contain multiple TUMAPs to maximize the chances of clinical success
by increasing the number of targets on cancer cells that they address. Phase 2 results
with IMA901 and IMA910 have shown improved survival in patients who respond to multiple
TUMAPs in both of these vaccines. immatics’ multi-peptide vaccines are ‘drug like’, i.e.
fully synthetic, off-the-shelf, easily scalable and stable.

immatics is based in Tuebingen and Martinsried (Munich), Germany and employs 70 people

For additional information on immatics please visit http://www.immatics.com or

        Paul Higham, CEO
        Dr. Nikola Wiegeler, Assistant to the Management
        immatics biotechnologies GmbH
        Phone: +49-7071-5397-110
        E-mail: media@immatics.com

        Citigate Dewe Rogerson
        David Dible / Chris Gardner / Sita Shah
        Phone: +44(0)207-638-9571
        E-mail: david.dible@citigatedr.co.uk

SOURCE immatics

Source: PR Newswire